References
-
1
Devlin N, Parkin D.
Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Health Economics.
2004;
13
437-452
-
2
National Institute for Clinical Excellence .
Drotrecogin alfa (activated) for severe sepsis.
Technology Appraisal.
2004;
84
-
3
Padkin A J, Goldfrad C, Young J D, Rowan K.
The prevalence of severe sepsis in the first 24 hours in the ICU, in England, Wales and Northern Ireland.
Intensive Care Medicine.
2001;
27
S252
-
4
Bernard G R, Vincent J L, Laterre P F. et al .
Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis.
New England Journal of Medicine.
2001;
344
699-709
-
5
Vincent J-L, Bernard G R, Beale R, Doig C, Putensen C, Dhainaut J-F. et al .
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment.
Critical Care Medicine.
2005;
33
2266-2277
-
6
Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus D C.
Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Anaesthesia.
2005;
60
155-162
-
7
Wright J C, Plenderleith L, Ridley S A.
Long term survival following intensive care - Subgroup analysis and comparison with the general population.
Anaesthesia.
2003;
58
637-642
-
8
Drabinski A, Williams G, Formica C.
Observational evaluation of health state utilities among a cohort of sepsis patients.
Value in Health.
2001;
4
130
-
9 Towse A. What is NICE’s threshold? An external view. In: Devlin N, Towse A (eds) Cost effectiveness thresholds: economic and ethical issues. London; Kings Fund/Office for Health Economics 2002
Dr. Saxon Ridley
Consultant in Anaesthesia and Intensive Care · Norfolk and Norwich University Hospital
Colney Lane · Norwich, NR4 7AU · UK ·
Email: saxon@domum.globalnet.co.uk
